Skip to main content
. 2021 Jan 8;11:591134. doi: 10.3389/fphar.2020.591134

FIGURE 1.

FIGURE 1

List price reductions of originator adalimumab on May 10 2019 versus list prices before loss of exclusivity (October 2018 or earlier) for all countries surveyed where list prices before and after loss of exclusivity of originator adalimumab were reported. Countries are sorted from high to low relative list price reduction (51% in Austria to 0% in several countries).